查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930025

抗凝血酶市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2025-2034）

Antithrombin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 123 Pages | 商品交期: 请询问到货日

价格

抗凝血酶市场成长驱动因子

到2025年，全球抗凝血酶市场规模达到3.8818亿美元，并持续稳定成长，主要受遗传性和后天性血栓形成中抗凝血治疗需求不断成长的推动。预计到2026年，市场规模将达到4.0334亿美元，到2034年将达到5.737亿美元，预测期内年复合成长率（CAGR）为4.50%。成长将缓慢但稳定，这得益于外科手术的增加、血浆衍生疗法的进步以及抗凝血酶浓缩物临床应用范围的扩大。2025年，欧洲在全球市场占据主导地位，市场占有率高达42.41%，这主要得益于其强大的血浆衍生药物生产能力和较高的产品获批率。

抗凝血酶是一种天然糖蛋白，能够抑制凝血酶和其他丝氨酸蛋白酶，在调节血液凝固过程中发挥关键作用。在治疗方面，抗凝血酶浓缩物广泛用于治疗遗传性抗凝血酶缺乏症、肝素抗性、重大手术以及体外膜氧合（ECMO）等疾病，使其成为复杂临床环境中重要的抗凝血治疗手段。

市场驱动因素与成长因素

市场成长的关键驱动因素之一是抗凝血酶的临床应用范围已扩展到传统血栓性疾病之外。目前，针对其在子痫前症、器官移植、连续性肾臟替代疗法（CRRT）、出血性休克和发炎性疾病中的作用的研究仍在继续。此外，遗传性抗凝血酶缺乏症的盛行率不断上升（估计影响0.02%至0.2%的一般人群），推动了对替代疗法的需求。

另一个主要成长因素是心血管手术、器官移植手术和新生儿手术数量的增加。在这些手术中，抗凝血酶替代疗法非常重要，尤其是在肝素抗性患者中。外科手术和重症监护环境中对先进抗凝血管理的需求不断成长，持续推动市场扩张。

市场限制因素与挑战

儘管需求强劲，但与抗凝血酶治疗相关的安全问题（例如出血风险、过敏反应和血栓栓塞併发症）仍然是市场限制因素。这些风险可能会限制其广泛应用，尤其是在监管有限的临床环境中。

高昂的治疗费用仍然是一个主要挑战，尤其是在中低收入国家。肝素、直接凝血酶抑制剂和直接口服抗凝血剂（DOAC）等替代抗凝血剂的出现，进一步限制了抗凝血酶的应用。此外，血浆衍生产品的复杂生产流程、对捐赠者的依赖性以及严格的监管要求，也导致了供应紧张和审批流程漫长。

市场机会与趋势

抗凝血酶，尤其是与肝素合併使用，其应用日益广泛，这是市场面临的一项重要机会。研究表明，联合疗法可以产生协同抗凝血效果，改善高风险患者的治疗效果。这一趋势在重症监护和外科手术领域正加速发展。

最显着的市场趋势之一是，在需要进行血栓预防的外科手术中，例如肝臟移植和心臟手术，抗凝血酶的使用日益增多。全球外科手术数量的不断成长，推动对抗凝血酶浓缩物的长期需求。

市场区隔分析

依来源

依来源划分，人类血浆来源的抗凝血酶将在2024年占据市场主导地位，市场占有率高达98.2%。这主要得益于其已确立的疗效和广泛的供应。同时，由于核准产品数量有限且研发过程复杂，重组抗凝血酶产品的市场仍受到限制。

依应用

预计2025年，治疗用途领域将引领市场，市场占有率将达95.9%。这主要得益于治疗抗凝血酶缺乏症和肝素抗性的高临床需求。同时，由于产品供应有限，研究和诊断用途领域的成长速度预计将较为缓慢。

依剂型划分

冻干粉剂因其稳定性佳、储存方便、临床应用广泛而备受认可，预计到2025年将占据市场主导地位，市场占有率高达97.7%。液体製剂由于产品种类有限，仍属于小众市场。

依最终使用者划分

截至2024年，医院和诊所占据最大市场占有率，主要得益于住院治疗和外科手术的应用。由于科研用途的增加，製药和生物技术行业预计将保持稳定成长。

区域展望

欧洲将在2026年以1.7072亿美元的市场规模引领全球市场，这得益于其完善的血浆采集基础设施和监管批准。亚太地区在2025年将达到1.4599亿美元，这主要得益于先天性缺陷病例数量的增加和国内生产规模的扩大。2025年，北美市场规模达到4,590万美元，但受到产品供应有限和严格监管的限制。世界其他地区由于血浆衍生疗法的可及性有限，成长速度放缓。

这份全球抗凝血酶市场报告对2025年至2034年的产业发展进行了详细全面的评估，其中2025年为基准年，2026年为估计年，2034年为预测年。报告评估了市场规模、市场价值、成长轨迹以及影响关键地区抗凝血酶疗法发展的结构性因素。

本研究基于原料来源、应用、剂型和最终用户进行了详细的市场细分分析，重点介绍了人类血浆衍生抗凝血酶、治疗应用、冻干剂型以及医院/诊所应用等方面的优势。报告涵盖欧洲、亚太、北美及世界其他地区，深入分析血浆采集基础设施、监管环境、产品供应及区域需求模式。

此外，报告还探讨了市场驱动因素、限制因素、机会和挑战，以及新兴趋势，例如临床应用范围的扩大、联合疗法的引进和外科手术中应用的增加。报告也评估了新冠疫情对需求趋势和临床应用的影响。竞争格局部分分析了CSL、Grifols S.A.和Octapharma AG等主要公司采取的策略举措，包括产品开发、临床试验、监管审批和产能扩张。

市场成长的驱动因素包括治疗应用范围的扩大、外科手术的增加以及抗凝血酶与肝素联合疗法的日益普及。 然而，高昂的治疗费用、安全隐患、对捐赠者的依赖以及严格的监管框架仍然是其广泛应用的障碍，尤其是在中低收入地区。

依地区划分，欧洲凭藉其强大的血浆衍生药物生产能力和较高的审批率，引领市场；其次是亚太地区，该地区由于先天性缺陷病例的增加和国内产量的扩大，药物可及性提高。北美和世界其他地区由于产品供应有限和监管限制，成长相对缓慢。总体而言，在临床需求、持续研究以及在高级护理和外科手术环境中的日益广泛应用的推动下，抗凝血酶市场预计将经历温和但稳定的长期成长。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 主要考察

  • 主要国家主要心血管疾病盛行率
  • 主要国家监管状况
  • 主要产业趋势（併购、合作、核准、上市等）
  • 新冠疫情对市场的影响
  • 概况：日本和韩国抗凝血酶市场

第5章 全球抗凝血酶市场分析、洞察与预测（2021-2034）

  • 依来源划分的市场分析、洞察与预测
    • 人血浆
    • 其他
  • 依应用划分的市场分析、洞察与预测
    • 治疗
    • 研究与诊断
  • 依剂型划分的市场分析、洞察与预测
    • 冻干粉
    • 液体
  • 依最终用户划分的市场分析、洞察与预测
    • 医院与诊所
    • 製药与生物技术
    • 研究机构
  • 依地区划分的市场分析、洞察与预测
    • 北美美洲
    • 欧洲
    • 亚太地区
    • 世界其他地区

第6章 北美抗凝血酶市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲抗凝血酶市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第8章 亚太地区抗凝血酶市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 东南亚
    • 亚太其他地区

第9章 世界其他地区抗凝血酶市场分析、洞察与预测（2021-2034）

第10章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
  • CSL
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • Grifols, S.A.
  • Medix Biochemica
  • Kedrion S.p.A.
  • Scripps Laboratories
  • LFB
Product Code: FBI100470

Growth Factors of antithrombin Market

The global antithrombin market was valued at USD 388.18 million in 2025 and is witnessing steady expansion driven by rising demand for anticoagulant therapies in both hereditary and acquired thrombotic conditions. The market is projected to grow to USD 403.34 million in 2026 and further reach USD 573.7 million by 2034, registering a CAGR of 4.50% during the forecast period. Growth remains moderate but consistent, supported by increasing surgical procedures, advancements in plasma-derived therapies, and broader clinical applications of antithrombin concentrates. Europe dominated the global market in 2025, accounting for 42.41% share, supported by strong plasma-derived medicinal product manufacturing capacity and high product approval rates.

Antithrombin is a naturally occurring glycoprotein that inhibits thrombin and other serine proteases, playing a crucial role in regulating blood coagulation. Therapeutically, antithrombin concentrates are widely used in patients with hereditary antithrombin deficiency, heparin resistance, major surgeries, and extracorporeal membrane oxygenation (ECMO), positioning the product as a critical anticoagulant therapy in complex clinical settings.

Market Drivers and Growth Factors

One of the primary drivers of market growth is the expanding clinical applications of antithrombin beyond traditional thrombotic disorders. Research continues to explore its role in preeclampsia, organ transplantation, continuous renal replacement therapy (CRRT), hemorrhagic shock, and inflammatory conditions. Additionally, the rising prevalence of hereditary antithrombin deficiency, estimated to affect 0.02%-0.2% of the general population, is driving demand for replacement therapy.

Another major growth factor is the increasing number of cardiovascular, transplant, and neonatal surgeries, where antithrombin supplementation is critical, particularly in patients exhibiting heparin resistance. The growing need for advanced anticoagulation management in surgical and intensive care settings continues to support market expansion.

Market Restraints and Challenges

Despite favorable demand, the market faces restraints due to safety concerns associated with antithrombin therapy, including bleeding risk, allergic reactions, and thromboembolic complications. These risks may limit widespread adoption, especially in less-monitored clinical environments.

High treatment costs remain a significant challenge, particularly in low- and middle-income countries. The availability of alternative anticoagulants such as heparin, direct thrombin inhibitors, and direct oral anticoagulants (DOACs) further restricts antithrombin uptake. Additionally, complex plasma-derived manufacturing processes, donor dependency, and stringent regulatory requirements contribute to supply limitations and extended approval timelines.

Market Opportunities and Trends

A key market opportunity lies in the growing adoption of antithrombin as combination therapy, particularly with heparin. Studies indicate that combined use produces a synergistic anticoagulant effect, enhancing therapeutic efficacy in high-risk patients. This trend is gaining traction in critical care and surgical settings.

One of the most notable market trends is the increasing use of antithrombin in surgical procedures, including liver transplantation and cardiac surgery, where thrombosis prevention is essential. The rising global surgical volume is reinforcing long-term demand for antithrombin concentrates.

Segmentation Analysis

By Source

By source, human plasma-derived antithrombin dominated the market, accounting for 98.2% share in 2024, supported by established efficacy and wide availability. Recombinant antithrombin products remain limited due to fewer approvals and higher development complexity.

By Application

The therapeutic segment led the market and is projected to capture 95.9% share in 2025, driven by high clinical demand for treating antithrombin deficiency and heparin resistance. The research & diagnostic segment is expected to grow at a slower pace due to limited product availability.

By Dosage Form

The lyophilized powder segment dominated with 97.7% market share in 2025, favored for stability, storage convenience, and widespread clinical use. Liquid formulations remain niche due to limited product offerings.

By End User

Hospitals & clinics accounted for the largest share in 2024, driven by inpatient treatments and surgical usage. The pharmaceutical & biotechnology segment is expected to grow steadily due to increasing research applications.

Regional Outlook

Europe led the global market, valued at USD 170.72 million in 2026, supported by extensive plasma collection infrastructure and regulatory approvals. Asia Pacific reached USD 145.99 million in 2025, driven by rising congenital deficiency cases and expanding domestic manufacturing. North America recorded USD 45.9 million in 2025, constrained by limited product availability and stringent regulations. The rest of the world showed slower growth due to restricted access to plasma-derived therapies.

Competitive Landscape

The market is led by CSL, supported by a strong plasma-derived product portfolio. Grifols, S.A. and Octapharma AG maintain significant positions through product expansion and global plasma networks. Other notable players include Takeda Pharmaceutical Company Limited and Kedrion S.p.A., all actively pursuing clinical studies, approvals, and manufacturing expansion to sustain competitiveness in the global antithrombin market.

Report Coverage

The global antithrombin market report provides a detailed and comprehensive assessment of the industry for the period 2025 to 2034, with 2025 as the base year, 2026 as the estimated year, and 2034 as the forecast year. The report evaluates market size, market value, growth trajectory, and structural developments influencing the evolution of antithrombin therapies across major regions.

The study includes in-depth segmentation analysis based on source, application, dosage form, and end user, highlighting the dominance of human plasma-derived antithrombin, therapeutic applications, lyophilized dosage forms, and hospital & clinic usage. Regional coverage spans Europe, Asia Pacific, North America, and the rest of the world, offering insights into plasma collection infrastructure, regulatory environments, product availability, and regional demand patterns.

Additionally, the report examines market drivers, restraints, opportunities, challenges, and emerging trends, including expanding clinical applications, combination therapy adoption, and increased surgical utilization. The impact of COVID-19 on demand dynamics and clinical usage is also assessed. The competitive landscape section analyzes strategic initiatives such as product development, clinical trials, regulatory approvals, and capacity expansions undertaken by leading companies including CSL, Grifols, S.A., and Octapharma AG.

Conclusion

The global antithrombin market demonstrated steady performance in 2025, reaching a market value of USD 388.18 million, supported by rising demand for anticoagulant therapies in hereditary antithrombin deficiency, heparin resistance, and complex surgical procedures. Continued expansion to USD 403.34 million in 2026 and a projected value of USD 573.7 million by 2034 reflects sustained clinical reliance on antithrombin concentrates despite the availability of alternative anticoagulants.

Market growth is driven by expanding therapeutic applications, increasing surgical volumes, and growing adoption of antithrombin in combination therapy with heparin. However, high treatment costs, safety concerns, donor dependency, and stringent regulatory frameworks continue to limit broader adoption, particularly in low- and middle-income regions.

Regionally, Europe maintains market leadership due to strong plasma-derived medicinal product manufacturing capacity and high approval rates, followed by Asia Pacific, where rising congenital deficiency cases and domestic production expansion are improving accessibility. North America and the rest of the world exhibit comparatively slower growth due to limited product availability and regulatory constraints. Overall, the antithrombin market is positioned for moderate but consistent long-term growth, supported by clinical necessity, ongoing research, and expanding use in advanced therapeutic and surgical settings.

Segmentation By Source, Application, Dosage Form, End User, and Region

By Source * Human Plasma

  • Others

By Application * Therapeutic

  • Research & Diagnostic

By Dosage Form * Lyophilized Powder

  • Liquid

By End User * Hospitals & Clinics

  • Pharmaceutical & Biotechnology Industry
  • Research Institutes

By Region * North America (By Source, Application, Dosage Form, End User, and Country/Sub-Region)

    • U.S.
    • Canada
  • Europe (By Source, Application, Dosage Form, End User, and Country/Sub-Region)
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Source, Application, Dosage Form, End User, and Country/Sub-Region)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Southeast Asia
    • Rest of the Asia Pacific
  • Rest of the World (By Source, Application, Dosage Form, and End User)

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Cardiovascular Diseases, By Key Countries
  • 4.2. Regulatory Scenario, By Key Countries
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Approvals, Launches etc.)
  • 4.4. Impact of COVID-19 on the Market
  • 4.5. Overview: Antithrombin Market in Japan & South Korea

5. Global Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Source
    • 5.1.1. Human Plasma
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Therapeutic
    • 5.2.2. Research & Diagnostic
  • 5.3. Market Analysis, Insights and Forecast - By Dosage Form
    • 5.3.1. Lyophilized Powder
    • 5.3.2. Liquid
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Hospitals & Clinics
    • 5.4.2. Pharmaceutical & Biotechnology Industry
    • 5.4.3. Research Institutes
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Rest of the World

6. North America Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Source
    • 6.1.1. Human Plasma
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Therapeutic
    • 6.2.2. Research & Diagnostic
  • 6.3. Market Analysis, Insights and Forecast - By Dosage Form
    • 6.3.1. Lyophilized Powder
    • 6.3.2. Liquid
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Hospitals & Clinics
    • 6.4.2. Pharmaceutical & Biotechnology Industry
    • 6.4.3. Research Institutes
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Source
    • 7.1.1. Human Plasma
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Therapeutic
    • 7.2.2. Research & Diagnostic
  • 7.3. Market Analysis, Insights and Forecast - By Dosage Form
    • 7.3.1. Lyophilized Powder
    • 7.3.2. Liquid
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Hospitals & Clinics
    • 7.4.2. Pharmaceutical & Biotechnology Industry
    • 7.4.3. Research Institutes
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. Germany
    • 7.5.2. UK
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Source
    • 8.1.1. Human Plasma
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Therapeutic
    • 8.2.2. Research & Diagnostic
  • 8.3. Market Analysis, Insights and Forecast - By Dosage Form
    • 8.3.1. Lyophilized Powder
    • 8.3.2. Liquid
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Hospitals & Clinics
    • 8.4.2. Pharmaceutical & Biotechnology Industry
    • 8.4.3. Research Institutes
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. South Korea
    • 8.5.6. Southeast Asia
    • 8.5.7. Rest of Asia Pacific

9. Rest of World Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Source
    • 9.1.1. Human Plasma
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Therapeutic
    • 9.2.2. Research & Diagnostic
  • 9.3. Market Analysis, Insights and Forecast - By Dosage Form
    • 9.3.1. Lyophilized Powder
    • 9.3.2. Liquid
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Hospitals & Clinics
    • 9.4.2. Pharmaceutical & Biotechnology Industry
    • 9.4.3. Research Institutes

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 10.2.1. CSL
    • 10.2.2. Octapharma AG
    • 10.2.3. Takeda Pharmaceutical Company Limited
    • 10.2.4. Grifols, S.A.
    • 10.2.5. Medix Biochemica
    • 10.2.6. Kedrion S.p.A.
    • 10.2.7. Scripps Laboratories
    • 10.2.8. LFB

List of Tables

  • Table 1: Global Antithrombin Market Revenue (USD million) Forecast, by Source, 2021-2034
  • Table 2: Global Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 3: Global Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 4: Global Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 5: Global Antithrombin Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 6: North America Antithrombin Market Revenue (USD million) Forecast, by Source, 2021-2034
  • Table 7: North America Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 8: North America Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 9: North America Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 10: North America Antithrombin Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 11: Europe Antithrombin Market Revenue (USD million) Forecast, by Source, 2021-2034
  • Table 12: Europe Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 13: Europe Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 14: Europe Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 15: Europe Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Antithrombin Market Revenue (USD million) Forecast, by Source, 2021-2034
  • Table 17: Asia Pacific Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 18: Asia Pacific Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 19: Asia Pacific Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 20: Asia Pacific Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Rest of the World Antithrombin Market Revenue (USD million) Forecast, by Source, 2021-2034
  • Table 22: Rest of the World Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 23: Rest of the World Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 24: Rest of the World Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034

List of Figures

  • Figure 1: Global Antithrombin Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Antithrombin Market Value Share (%), by Source, 2025 & 2034
  • Figure 3: Global Antithrombin Market Value Share (%), by Dosage Form, 2025 & 2034
  • Figure 4: Global Antithrombin Market Value Share (%), by Application, 2025 & 2034
  • Figure 5: Global Antithrombin Market Value Share (%), by End User, 2025 & 2034
  • Figure 6: Global Antithrombin Market Value (USD million), by Region, 2025 & 2034
  • Figure 7: North America Antithrombin Market Value (USD million), by Source, 2025 & 2034
  • Figure 8: North America Antithrombin Market Value Share (%), by Source, 2025
  • Figure 9: North America Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 10: North America Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 11: North America Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 12: North America Antithrombin Market Value Share (%), by Application, 2025
  • Figure 13: North America Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 14: North America Antithrombin Market Value Share (%), by End User, 2025
  • Figure 15: North America Antithrombin Market Value (USD million), By Country, 2025 & 2034
  • Figure 16: North America Antithrombin Market Value Share (%), By Country, 2025
  • Figure 17: Europe Antithrombin Market Value (USD million), by Source, 2025 & 2034
  • Figure 18: Europe Antithrombin Market Value Share (%), by Source, 2025
  • Figure 19: Europe Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 20: Europe Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 21: Europe Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 22: Europe Antithrombin Market Value Share (%), by Application, 2025
  • Figure 23: Europe Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 24: Europe Antithrombin Market Value Share (%), by End User, 2025
  • Figure 25: Europe Antithrombin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Antithrombin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Antithrombin Market Value (USD million), by Source, 2025 & 2034
  • Figure 28: Asia Pacific Antithrombin Market Value Share (%), by Source, 2025
  • Figure 29: Asia Pacific Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 30: Asia Pacific Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 31: Asia Pacific Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 32: Asia Pacific Antithrombin Market Value Share (%), by Application, 2025
  • Figure 33: Asia Pacific Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 34: Asia Pacific Antithrombin Market Value Share (%), by End User, 2025
  • Figure 35: Asia Pacific Antithrombin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Antithrombin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Rest of the World Antithrombin Market Value (USD million), by Source, 2025 & 2034
  • Figure 38: Rest of the World Antithrombin Market Value Share (%), by Source, 2025
  • Figure 39: Rest of the World Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 40: Rest of the World Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 41: Rest of the World Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 42: Rest of the World Antithrombin Market Value Share (%), by Application, 2025
  • Figure 43: Rest of the World Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 44: Rest of the World Antithrombin Market Value Share (%), by End User, 2025
  • Figure 45: Global Antithrombin Market Share (%), By Company, 2025